Open Orphan PLC Value the Markets Webinar
24 Ottobre 2019 - 8:01AM
RNS Non-Regulatory
TIDMORPH
Open Orphan PLC
24 October 2019
24 October 2019
Open Orphan Plc
("Open Orphan" or the "Company")
Value the Markets Webinar
Open Orphan's Maurice Treacy Hosts Value the Markets Webinar
Open Orphan, a European-focussed, rare and orphan drug
consulting services platform, announces that the Company's Chief
Commercial Officer, Maurice Treacy, will be hosting a webinar
alongside Value the Markets on Wednesday 30(th) October 2019 at
19:00 (UK time).
Maurice Treacy will take the opportunity to update existing and
potential shareholders on Open Orphan and will provide an insight
on the Company's Genomic Health Data platform, Europe's first rare
disease, advocacy-led genomic database. Maurice will also discuss
how and why it is now so important for pharmaceutical companies to
have access to patient data when developing new drugs.
For those wishing to join, the webinar will be available through
webcast or dial-in facilities via the details provided below:
Webcast URL Link:
https://vtm.clickmeeting.com/orph
Dial-in details:
UK dial-in number: +44 (20) 7048 4146
Irish dial-in number: +353 (76) 680 3062
Participant PIN: 214883#
When prompted, please provide participant's pin code followed by
# key
Enquiries:
Open Orphan Plc Tel: +353 (0)1 6440007
Cathal Friel, Chief Executive Officer
Arden Partners (Nominated Adviser and Joint Broker) Tel: +44
(0)20 7614 5900
John Llewellyn-Lloyd / Ruari McGirr / Benjamin Cryer
Davy (Euronext Growth Adviser and Joint Broker) Tel: +353 (0)1
679 6363
Anthony Farrell (Corporate Finance)
Camarco (Financial PR) Tel: +44 (0)20 3757 4980
Tom Huddart / Billy Clegg / Daniel Sherwen
Notes to Editors:
Open Orphan plc is a European-focused, rare and orphan drug
consulting services platform. The Company intends to roll up a
number of orphan drug services business. Open Orphan has two data
driven digital platforms, a Genomic Health Data Platform, which is
establishing a rare disease database and a Virtual Rep platform
enabling pharmaceutical companies to engage key opinion leaders and
physicians. The Company is targeting rapid growth in one of the
fastest growing sectors in the global pharmaceutical industry
targeting under-supplied treatment for life threatening or very
serious diseases and rare disorders.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAMJBLTMBJTBRL
(END) Dow Jones Newswires
October 24, 2019 02:01 ET (06:01 GMT)
Grafico Azioni Venn Life Sciences (LSE:VENN)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Venn Life Sciences (LSE:VENN)
Storico
Da Apr 2023 a Apr 2024
